Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.7% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price traded down 2.7% during mid-day trading on Tuesday . The stock traded as low as $34.76 and last traded at $35.03. 304,832 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 621,542 shares. The stock had previously closed at $36.00.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Guggenheim increased their price objective on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Truist Financial assumed coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 14th. They set a “buy” rating and a $56.00 price objective on the stock. Wedbush raised their price target on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, September 8th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $60.88.

Dianthus Therapeutics Stock Performance

The business’s fifty day moving average price is $31.73 and its 200-day moving average price is $23.56. The stock has a market cap of $1.13 billion, a PE ratio of -10.78 and a beta of 1.58.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 16.56% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. US Bancorp DE raised its stake in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares during the period. GAMMA Investing LLC raised its stake in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after acquiring an additional 3,758 shares during the period. Tower Research Capital LLC TRC raised its stake in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the period. Finally, AlphaQuest LLC bought a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $94,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.